The MDM2-p53 pathway revisited
doi: 10.7555/JBR.27.20130030
This work was supported by the National Institutes of Health (NIH) grants R01 CA112029 and R01 CA121211 and a Susan G Komen Foundation grant BCTR0707731 (to R.Z.).
- Received Date: 2013-03-15
- Publish Date: 2013-07-28
-
Key words:
- oncogene /
- tumor suppressor /
- MDM2-p53 interaction /
- cancer therapy
Abstract: The p53 tumor suppressor is a key transcription factor regulating cellular pathways such as DNA repair, cell cycle, apoptosis, angiogenesis, and senescence. It acts as an important defense mechanism against cancer onset and progression, and is negatively regulated by interaction with the oncoprotein MDM2. In human cancers, the TP53 gene is frequently mutated or deleted, or the wild-type p53 function is inhibited by high levels of MDM2, leading to downregulation of tumor suppressive p53 pathways. Thus, the inhibition of MDM2-p53 interaction presents an appealing therapeutic strategy for the treatment of cancer. However, recent studies have revealed the MDM2-p53 interaction to be more complex involving multiple levels of regulation by numerous cellular proteins and epigenetic mechanisms, making it imperative to reexamine this intricate interplay from a holistic viewpoint. This review aims to highlight the multifaceted network of molecules regulating the MDM2-p53 axis to better un-derstand the pathway and exploit it for anticancer therapy.
Citation: | Subhasree Nag, Jiangjiang Qin, Kalkunte S. Srivenugopal, Minghai Wang, Ruiwen Zhang. The MDM2-p53 pathway revisited[J]. The Journal of Biomedical Research, 2013, 27(4): 254-271. doi: 10.7555/JBR.27.20130030 |